Lima Corporate, an Italian company providing reconstructive orthopaedic solutions to surgeons, is celebrating the 10th anniversary of Trabecular Titanium (TT), Lima’s proprietary 3D printing technology.
Lima: 10 Years of Trabecular Titanium
2 min read Premium comments
Secondary
As indicated in the March 14, 2017 news release, “…Lima decided to strengthen a partnership with Arcam to further develop the potential of the TT technology by using Arcam’s knowledge and experience with 3D printing in other industries.”
“We are very proud to support Lima on their impressive additive manufacturing journey. As a pioneer of additive manufacturing, Lima has taken the lead in transforming the orthopaedic industry and thereby transforming Arcam,” said Magnus René, CEO of Arcam AB, a Swedish company focused on additive manufacturing.
The news release states, “In 2007, the first acetabular cup, the Lima Delta TT Cup, was born with the objective to satisfy the demands of surgeons for better implant performance and outcomes; after obtaining the CE mark, the Delta TT Cup was implanted for the first time in Italy and since then it has been available in the global market. Following this experience over the past 10 years, Lima has developed a product portfolio covering different anatomical areas from hip to extremities as well as tailored solutions for patient-specific needs utilizing TT.”
“Lima is known for innovation and our focus on pre-clinical and clinical research to support innovation. This milestone is a great recognition for Lima and our supporting surgeons that believed in this technology 10 years ago and have continued this exciting path with us. From this innovation to many others, Lima will continue to grow and develop solutions to assist orthopaedic surgeons in restarting the emotion of motion” said Luigi Ferrari, Lima Corporate CEO.
Asked how the company plans to celebrate, Luigi Ferrari told OTW, “Lima will run many different activities during the entire year instead of a single event. As the only company with 10 years in 3D printing, we will focus all of our communications around the technology behind Trabecular Titanium (TT). During our Medical Education Events, specific session on TT will be held with a focus on the experience and clinical data of our surgeons.”
“Internally, starting last year, we have provided training for our employees and sales teams as well as producing a number of scientific and clinical documents that explain the history and relevant data supporting TT. Also within our offices, the entire company has been branded with ‘10 years of TT – A Decade of Distinction.’”
“Our campaign will be focused on communication about the Trabecular Titanium technology and inform surgeons and the market about this important milestone which establishes Lima as the pioneer of 3D printing. We have also a synergic cooperation together with Arcam to run aligned activities and at upcoming congresses. There will be symposia, presentations and posters to scientifically support TT. All of our activities can be followed through Lima’s LinkedIn page.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.